CA2613141A1 - Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders - Google Patents

Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders Download PDF

Info

Publication number
CA2613141A1
CA2613141A1 CA002613141A CA2613141A CA2613141A1 CA 2613141 A1 CA2613141 A1 CA 2613141A1 CA 002613141 A CA002613141 A CA 002613141A CA 2613141 A CA2613141 A CA 2613141A CA 2613141 A1 CA2613141 A1 CA 2613141A1
Authority
CA
Canada
Prior art keywords
compound
sirtuin
formula
activating compound
further embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002613141A
Other languages
English (en)
French (fr)
Inventor
Michael Milburn
Jill Milne
Johan Auwerx
Carmen Argmann
Marie Lagouge
Michelle Dipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirtris Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2613141A1 publication Critical patent/CA2613141A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
CA002613141A 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders Abandoned CA2613141A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US69744305P 2005-07-07 2005-07-07
US60/697,443 2005-07-07
US73652805P 2005-11-14 2005-11-14
US60/736,528 2005-11-14
US75360605P 2005-12-23 2005-12-23
US60/753,606 2005-12-23
US78380206P 2006-03-16 2006-03-16
US60/783,802 2006-03-16
PCT/US2006/026272 WO2007008548A2 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Publications (1)

Publication Number Publication Date
CA2613141A1 true CA2613141A1 (en) 2007-01-18

Family

ID=37492426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002613141A Abandoned CA2613141A1 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Country Status (6)

Country Link
EP (1) EP1898897A2 (https=)
JP (1) JP2009500357A (https=)
CN (1) CN103055313A (https=)
AU (1) AU2006269459B2 (https=)
CA (1) CA2613141A1 (https=)
WO (1) WO2007008548A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019143560A1 (en) * 2018-01-16 2019-07-25 The Regents Of The University Of California Methods for promoting mitochondrial biogenesis in neural cells

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
US20090162457A1 (en) * 2005-10-26 2009-06-25 Kao Corporation Resveratrol and/or grape leaf extract as i. a. endurance improver, anti-aging agent, muscle strength improver
US7718830B2 (en) 2006-04-24 2010-05-18 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7618966B2 (en) 2006-04-24 2009-11-17 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
AU2007244978B2 (en) * 2006-04-24 2013-05-30 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
US20100047177A1 (en) * 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
US20100130597A1 (en) 2007-07-06 2010-05-27 The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service Dna-pkcs modulates energy regulation and brain function
WO2009054994A2 (en) * 2007-10-23 2009-04-30 President And Fellows Of Harvard College Sirt-3 related methods and compositions for mimicking exercise
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
CA2729128C (en) 2008-07-03 2016-05-31 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
JP5655243B2 (ja) * 2009-10-19 2015-01-21 国立大学法人 熊本大学 インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
MX2012004995A (es) 2009-10-29 2012-10-03 Sirtris Pharmaceuticals Inc Piridinas biciclicas y analogos como moduladores de sirtuina.
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
JP5581071B2 (ja) * 2010-02-03 2014-08-27 花王株式会社 ミトコンドリア機能向上剤
WO2012008549A1 (ja) * 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
EP2610249B1 (en) * 2010-08-26 2017-10-11 Kyoto University Pluripotent stem cell cardiomyocyte differentiation-promoting agent
JP5850503B2 (ja) * 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 筋ジストロフィーを処置するための組成物
AU2015201809B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
RU2543539C2 (ru) * 2010-12-20 2015-03-10 Хилл'С Пет Ньютришн, Инк. Кормовые композиции для домашних животных, вызывающие чувство сытости
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
KR101451357B1 (ko) * 2011-02-18 2014-10-15 주식회사 스템디알 Ｓｉｒｔ１ 발현 유도 물질을 포함하는 패혈증 또는 패혈증 쇼크의 예방 또는 치료용 조성물
WO2012145749A1 (en) * 2011-04-22 2012-10-26 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
CA2840516A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
JP6155191B2 (ja) * 2011-10-02 2017-06-28 キユーピー株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途
US8916528B2 (en) 2011-11-16 2014-12-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
KR101996343B1 (ko) 2012-01-27 2019-07-05 고쿠리츠 다이가쿠 호진 교토 다이가쿠 전능성 줄기세포의 심근분화 유도방법
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014014816A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
WO2014014819A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
JP6351567B2 (ja) 2013-03-08 2018-07-04 国立大学法人京都大学 Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤
CN105228627B (zh) * 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
US20160113893A1 (en) * 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
US20160101072A1 (en) * 2013-06-12 2016-04-14 Proximagen Limited Therapeutic uses of enzyme inhibitors
CA2928656C (en) * 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
JP6651218B2 (ja) 2014-05-30 2020-02-19 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
JP6545256B2 (ja) * 2015-03-31 2019-07-17 新興和製薬株式会社 レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物
EP3347024A2 (en) * 2015-09-08 2018-07-18 Ecole Polytechnique Federale de Lausanne (EPFL) Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
EP3393467B1 (en) 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
WO2018002215A1 (en) * 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
JPWO2018079719A1 (ja) * 2016-10-27 2019-09-19 サントリーホールディングス株式会社 ＰＧＣ−１α活性化用組成物
CN108066348A (zh) * 2016-11-16 2018-05-25 成都普睿法药物研发有限公司 土大黄苷在制备抗肺纤维化药物中的应用
CN106580951B (zh) * 2016-11-17 2019-07-30 珠海雅光生物工程有限公司 一种黄烷酮化合物的新用途
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
JP2018172346A (ja) * 2017-03-31 2018-11-08 株式会社東洋新薬 妊娠サポート用組成物
EP3388072A1 (en) * 2017-04-10 2018-10-17 Universität Leipzig Ubiquinone-independent cytoplasmic dihydroorotate dehydrogenase for use as medicament
ES3004332T3 (en) 2017-05-17 2025-03-12 Univ De Valencia Estudi General Treating and preventing amyotrophic lateral sclerosis with nicotinamide riboside and pterostilbene
WO2019043846A1 (ja) 2017-08-30 2019-03-07 大塚製薬株式会社 ケンペロール類縁体含有組成物
CN109896997A (zh) * 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
CA3122246C (en) * 2018-12-05 2025-06-10 Celagenex Research (India) Pvt. Ltd. Synergistic compositions of bioactive agents to optimize cell health
KR102712818B1 (ko) * 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
WO2021071965A1 (en) * 2019-10-08 2021-04-15 Applied Therapeutics Inc. Aldose reductase inhibitors for treatment of phosphomannomutase 2 deficiency
CN112516138B (zh) * 2020-12-15 2022-03-29 中国人民解放军陆军军医大学 化合物yx-2102在制备治疗肺纤维化药物中的应用
ES2974212T3 (es) * 2020-12-18 2024-06-26 Nuvamid Sa Derivados de mononucleótidos de nicotinamida en el tratamiento y la prevención de la enfermedad de células falciformes
CN117580573A (zh) * 2021-06-22 2024-02-20 南京纽邦生物科技有限公司 L-麦角硫因用于缓解和预防年龄相关的视力退化
WO2022268047A1 (en) 2021-06-22 2022-12-29 Nanjing Nutrabuilding Bio-Tech Co., Ltd Use of L-ergothioneine to ameliorate and prevent age-related vitreous degeneration
CN113663083A (zh) * 2021-08-16 2021-11-19 重庆第二师范学院 一种漆黄素磷脂复合物和减肥药物/保健食品及其应用
CN114668845B (zh) * 2022-04-06 2023-04-11 北京清华长庚医院 肝脏Sirt5蛋白在制备抑制糖异生和提高糖耐量的产品中的应用
CN114920805B (zh) * 2022-05-06 2022-12-06 浙江湃肽生物股份有限公司 一种具有改善皱纹活性的新型红蝎毒素及包含其的组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072583A (ja) * 1999-09-07 2001-03-21 Sunstar Inc 高脂血症の予防又は治療用組成物
US6878751B1 (en) * 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
WO2002081651A2 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
WO2003099040A1 (en) * 2002-05-27 2003-12-04 Advance Holdings Limited Dietary supplements from wine vinasses and relevant production process
WO2004105517A1 (en) * 2003-05-27 2004-12-09 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof
JP2007530417A (ja) * 2003-07-01 2007-11-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞及び生物の寿命及びストレス応答を操作するための組成物
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
JP4963670B2 (ja) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ， エルエルシー 栄養補助サプリメントおよびそれを処理する方法
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019143560A1 (en) * 2018-01-16 2019-07-25 The Regents Of The University Of California Methods for promoting mitochondrial biogenesis in neural cells

Also Published As

Publication number Publication date
JP2009500357A (ja) 2009-01-08
EP1898897A2 (en) 2008-03-19
AU2006269459B2 (en) 2013-02-07
WO2007008548A2 (en) 2007-01-18
CN103055313A (zh) 2013-04-24
AU2006269459A1 (en) 2007-01-18
WO2007008548A3 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
AU2006269459B2 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070149466A1 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070248590A1 (en) Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US7998974B2 (en) Fused heterocyclic compounds and their use as sirtuin modulators
EP1910362B9 (en) Imidazopyridine derivatives as sirtuin modulating agents
US20110009496A1 (en) Resveratrol formulations
US20090069301A1 (en) Acridine and Quinoline Derivatives as Sirtuin Modulators
US20090163476A1 (en) N-Phenyl Benzamide Derivatives as Sirtuin Modulators
CN101257897A (zh) 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
WO2008073451A2 (en) Benzoimidazole derivatives as sirtuin (sir) modulating compounds
WO2006094209A2 (en) N-benzimidazolylalkyl-substituted amide sirtuin modulators
CA2610854A1 (en) Nicotinamide riboside and analogues thereof
WO2009085226A2 (en) Inhibitors of cdc2-like kinases (clks) and methods of use thereof
WO2009158646A1 (en) Therapeutic compunds and related methods of use
WO2006094210A2 (en) Tetrahydroquinoxalinone sirtuin modulators
WO2006094246A2 (en) N-arylmethyl benzamide sirtuin modulators
WO2006094233A1 (en) N,n'-dicyclic isothiourea sirtuin modulators
WO2006094248A1 (en) Aryl-substituted cyclic sirtuin modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140430